• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Real-world data backs digital therapeutic for substance use disorder from Pear Therapeutics

Real-world data backs digital therapeutic for substance use disorder from Pear Therapeutics

October 25, 2022 By Sean Whooley

Pear Therapeutics reSET_Check_In (1)
Pear Therapeutics designed the reSET prescription digital therapeutic for the treatment of substance abuse disorder. [Image courtesy of Pear Therapeutics]
Pear Therapeutics (Nasdaq:PEAR) announced positive data supporting its reSET prescription digital therapeutic (PDT).

Boston-based Pear designed FDA-authorized reSET for the treatment of substance use disorder (SUD). That includes alcohol, cannabis, cocaine, and stimulants like methamphetamines.

The real-world study demonstrated high rates of engagement, retention and abstinence from substances with reSET through 12 weeks. The American Journal on Addictions (AJA) published the data.

reSET provides cognitive behavioral therapy as an adjunct to a contingency management system. Its indication covers patients aged 18 years and older currently enrolled in outpatient treatment under clinician supervision. The 12-week (90-day) prescription-only treatment covers SUD patients not currently on opioid replacement therapy. Those patients do not abuse alcohol solely. They also do not abuse opioids as their primary substance of abuse.

The data from Pear Therapeutics’ study

The real-world observational analysis covered an all-comer population of 602 patients. It evaluated substance use as a composite of self-reports and urine screens.

More than 74% of patients remained in reSET treatment and used their PDT during the final four weeks. Abstinence rates during that period totaled 62%. That analysis treated missing data as a positive urine screen. Meanwhile, abstinence came in at 86% where authors excluded missing data from the analysis.

Of patients using reSET appropriately, 81% presented abstinence and the study retained 92% at 12 weeks. That includes patients on four or more lessons per week on average in the first four weeks.

“Nearly half of people who begin a treatment program stop within the first three months, which makes it challenging to effectively treat patients throughout their entire recovery journey,” said Dr. Yuri Maricich, CMO, Pear Therapeutics. “The high rates of engagement and retention we observed in this analysis are especially encouraging as they demonstrate the potential benefit of reSET in treating patients in diverse and naturalistic real-world settings with substance use disorder, a population in need of effective therapies.”

Read: What does the future hold for AI in medical devices?

Filed Under: Clinical Trials, Digital Health, Health Technology, Software / IT Tagged With: Pear Therapeutics

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy